Skip to main content

CAR T cell Therapy Market by 2023 Briefing by Segmentation, Technology and Trends

Global CAR T cell Therapy Market is projected to reach USD 8716.06 Million by 2025 at a CAGR of 58.52% during the review period from 2019 to 2025. Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy used for cancer treatment. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells.
Growing prevalence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, and rise in the number of cell therapy clinical studies are driving the growth of the global CAR T Cell Therapy market. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Moreover, the growing pharmaceutical industry is also expected to boost market growth.
Segment Analysis
The global CAR T cell therapy market, by target antigen, has been segmented into CD19, CD22, and others. The CD19 target antigen segment accounted for a value of USD 342.56 million in 2018. On the basis of application, the global CAR T cell therapy market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and others.
Market Players
Market Research Future (MRFR) recognizes the following companies as key players in the global CAR T Cell therapy market that include Novartis AG (Switzerland), Pfizer, Inc. (US), Kite Pharma (US), Cellectis (France), Autolus Therapeutics PLC (UK), CARsgen Therapeutics (China), Juno Therapeutics (US), Sorrento Therapeutics (US), Legend Biotech (US), Mustang Bio (US), and others.
Regional Analysis
The global CAR T cell therapy market, based on region, is divided into the US, Europe, China, and the rest of the world.
The US is expected to hold the largest share of the global CAR T cell therapy market. This is owing to the increasing cases of cancer in the country. Europe showed a considerable amount of growth in the market due to an increase in the occurrences of hematologic cancer such as leukemia, lymphoma, and multiple myeloma. Europe held a market share of 9.15% in the global CAR T cell therapy market. China is estimated to significantly grow in the global market due to the developing healthcare infrastructure and increasing disposable income. Also, the market in the Middle East & Africa is expected to show the least growth owing to limited healthcare access and affordability among the population.
Key Findings of the Study
  • The Global CAR T cell Therapy Market is projected to reach USD 8716.06 Million by 2025 at a CAGR of 58.52% during the review period from 2019 to 2025.
  • The US accounted for the largest share of the global market due to the rising prevalence of cancer in the country.
  • The CD19 target antigen accounted for the largest target antigen segment, with a revenue of USD 56 million in 2018.
About Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
+1 646 845 9312 | Email: sales@marketresearchfuture.com
Labels:

Comments

Post a Comment

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La R...
3 comments
Read more

Krabbe Disease Treatment Market Set to Surge Significantly with New Innovations, Application, Recent Technology

  Krabbe Disease Treatment Market Overview Krabbe disease is an incurable medical condition where the protective coating of nerve cells around the brain are destroyed which causing nerve damage. The global Krabbe disease treatment market can reach a significant valuation, exhibiting a steady CAGR over the forecast period of 2016 to 2022, as per a research report published by Market Research Future (MRFR). The market has been growing continuously on account of increasing incidence of Krabbe disease across the globe. Classification of Krabbe disease under orphan disease has propelled the growth of the market. Pharmaceutical companies receive incentives to develop medicine for rare disease along with reduced fees in protocol assistance and protection from competition after the medicine is marketed. Increased government funding for drug development and easy approvals, tax credits on clinical research, reduction in the amount of registration fees also aid the growth of the market. These...
Post a Comment
Read more

Peptic Ulcer Drugs Market Rapid Development By Manufactures Business Growth Future

  Peptic Ulcer Drugs Market Scenario: Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022. Thus, the market is expected to show an average growth at a CAGR of 3.8 % from 2016 to 2022. The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics. Avail a Free Sample@  https://www.market...
Post a Comment
Read more